Pancreatic cancer environment: from patient-derived models to single-cell omics

IF 3 4区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Molecular omics Pub Date : 2024-02-14 DOI:10.1039/D3MO00250K

Ao Gu, Jiatong Li, Shimei Qiu, Shenglin Hao, Zhu-Ying Yue, Shuyang Zhai, Meng-Yao Li and Yingbin Liu

{"title":"Pancreatic cancer environment: from patient-derived models to single-cell omics","authors":"Ao Gu, Jiatong Li, Shimei Qiu, Shenglin Hao, Zhu-Ying Yue, Shuyang Zhai, Meng-Yao Li and Yingbin Liu","doi":"10.1039/D3MO00250K","DOIUrl":null,"url":null,"abstract":"<p >Pancreatic cancer (PC) is a highly malignant cancer characterized by poor prognosis, high heterogeneity, and intricate heterocellular systems. Selecting an appropriate experimental model for studying its progression and treatment is crucial. Patient-derived models provide a more accurate representation of tumor heterogeneity and complexity compared to cell line-derived models. This review initially presents relevant patient-derived models, including patient-derived xenografts (PDXs), patient-derived organoids (PDOs), and patient-derived explants (PDEs), which are essential for studying cell communication and pancreatic cancer progression. We have emphasized the utilization of these models in comprehending intricate intercellular communication, drug responsiveness, mechanisms underlying tumor growth, expediting drug discovery, and enabling personalized medical approaches. Additionally, we have comprehensively summarized single-cell analyses of these models to enhance comprehension of intercellular communication among tumor cells, drug response mechanisms, and individual patient sensitivities.</p>","PeriodicalId":19065,"journal":{"name":"Molecular omics","volume":" 4","pages":" 220-233"},"PeriodicalIF":3.0000,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular omics","FirstCategoryId":"99","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/mo/d3mo00250k","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Pancreatic cancer (PC) is a highly malignant cancer characterized by poor prognosis, high heterogeneity, and intricate heterocellular systems. Selecting an appropriate experimental model for studying its progression and treatment is crucial. Patient-derived models provide a more accurate representation of tumor heterogeneity and complexity compared to cell line-derived models. This review initially presents relevant patient-derived models, including patient-derived xenografts (PDXs), patient-derived organoids (PDOs), and patient-derived explants (PDEs), which are essential for studying cell communication and pancreatic cancer progression. We have emphasized the utilization of these models in comprehending intricate intercellular communication, drug responsiveness, mechanisms underlying tumor growth, expediting drug discovery, and enabling personalized medical approaches. Additionally, we have comprehensively summarized single-cell analyses of these models to enhance comprehension of intercellular communication among tumor cells, drug response mechanisms, and individual patient sensitivities.

Abstract Image

查看原文本刊更多论文

胰腺癌环境：从患者衍生模型到单细胞全息研究

胰腺癌（PC）是一种高度恶性的癌症，具有预后差、异质性高、异细胞系统复杂等特点。选择合适的实验模型来研究其进展和治疗至关重要。与细胞系衍生模型相比，患者衍生模型能更准确地反映肿瘤的异质性和复杂性。本综述初步介绍了相关的患者来源模型，包括患者来源异种移植（PDX）、患者来源器官组织（PDO）和患者来源外植体（PDE），它们对于研究细胞通讯和胰腺癌进展至关重要。我们强调了这些模型在理解错综复杂的细胞间通讯、药物反应性、肿瘤生长机制、加快药物发现和实现个性化医疗方法方面的应用。此外，我们还全面总结了这些模型的单细胞分析，以加深对肿瘤细胞间交流、药物反应机制和患者个体敏感性的理解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular omics Biochemistry, Genetics and Molecular Biology-Biochemistry

CiteScore

5.40

自引率

3.40%

发文量

期刊介绍： Molecular Omics publishes high-quality research from across the -omics sciences. Topics include, but are not limited to: -omics studies to gain mechanistic insight into biological processes – for example, determining the mode of action of a drug or the basis of a particular phenotype, such as drought tolerance -omics studies for clinical applications with validation, such as finding biomarkers for diagnostics or potential new drug targets -omics studies looking at the sub-cellular make-up of cells – for example, the subcellular localisation of certain proteins or post-translational modifications or new imaging techniques -studies presenting new methods and tools to support omics studies, including new spectroscopic/chromatographic techniques, chip-based/array technologies and new classification/data analysis techniques. New methods should be proven and demonstrate an advance in the field. Molecular Omics only accepts articles of high importance and interest that provide significant new insight into important chemical or biological problems. This could be fundamental research that significantly increases understanding or research that demonstrates clear functional benefits. Papers reporting new results that could be routinely predicted, do not show a significant improvement over known research, or are of interest only to the specialist in the area are not suitable for publication in Molecular Omics.